US Stock Insider Trading | Neurosecretory Biological Sciences disclosed 35 insider trading transactions on February 17

K-LinePoet · 2026-02-20T20:12:20+00:00

On February 17, 2026, Neurosecretory Biological Sciences (NBIX) disclosed 35 insider trading transactions. Director GORMAN KEVIN CHARLES sold 34,000 shares on February 13, 2026.【Recent Insider Transactions】| Disclosure Date | Position | Name | Transaction Date | Buy/Sell | Quantity | Price per Share (USD) | Total Amount (USD) || --- | --- | --- | --- | --- | --- | --- | --- || February 17, 2026 | Executive | BENEVICH ERIC | February 13, 2026 | Sell | 11,000 | 124.12 | 1.3833 million |

K-LinePoet

2026-02-20 20:12:20

On February 17, 2026, Neurocrine Biosciences (NBIX) disclosed 35 insider trading transactions. Director GORMAN KEVIN CHARLES sold 34,000 shares on February 13, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 17, 2026	Executive	BENEVICH ERIC	February 13, 2026	Sell	11,100	124.12	1.3833 million
February 17, 2026	Executive	ABERNETHY MATT	February 12, 2026	Sell	1,151	123.10	141,700
February 17, 2026	Director	Gano Kyle	February 13, 2026	Sell	7,973	124.12	989,600
February 17, 2026	Executive	BENEVICH ERIC	February 12, 2026	Sell	1,082	123.10	133,200
February 17, 2026	Executive	Boyer David W.	February 12, 2026	Sell	864	123.10	106,400
February 17, 2026	Executive	Boyer David W.	February 13, 2026	Sell	7,188	124.12	892,200
February 17, 2026	Director	GORMAN KEVIN CHARLES	February 13, 2026	Sell	40,300	124.12	5.0027 million
February 17, 2026	Director	Gano Kyle	February 12, 2026	Sell	2,648	123.10	326,000
February 17, 2026	Executive	Cooke Julie	February 12, 2026	Sell	749	123.10	92,200
February 17, 2026	Executive	ABERNETHY MATT	February 13, 2026	Sell	7,973	124.12	989,600

[Company Profile]

Neurocrine Biosciences, Inc. was incorporated in California in January 1992 and re-incorporated in Delaware in May 1996. The company is a biopharmaceutical focused on neuroscience, dedicated to discovering, developing, and commercializing treatments for unmet neurological, psychiatric, endocrine, and immune system diseases. Its product portfolio includes therapies approved by the U.S. Food and Drug Administration for tardive dyskinesia, Huntington’s disease chorea, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, with a diversified pipeline ranging from small molecules to gene therapies in core therapeutic areas.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.